Biomarkers of neuroendocrine tumors

被引：7

作者：

d'Herbomez, Michele ^{[1
,2
]}

Coppin, Lucie ^{[1
,2
]}

Bauters, Catherine ^{[3
]}

Rouaix-Emery, Nathalie ^{[2
]}

Carnaille, Bruno ^{[1
,4
]}

Do Cao, Christine ^{[3
]}

机构：

[1] Univ Lille, Fac Med, Lille, France

[2] CHRU Lille, Dept Biochim, Ctr Biol Pathol Genet, Lille, France

[3] CHRU Lille, Clin Endocrinol, Lille, France

[4] CHRU Lille, Serv Chirurg Endocrinienne, Lille, France

来源：

ANNALES DE BIOLOGIE CLINIQUE | 2016年 / 74卷 / 06期

关键词：

biomarkers; neuroendocrine tumors; chromogranin A; metanephrines; calcitonin; serotonin; proinsulin; progastrin; gastrin; peptides; MEDULLARY-THYROID CARCINOMA; ENETS CONSENSUS GUIDELINES; NEURON-SPECIFIC ENOLASE; PROGASTRIN-RELEASING PEPTIDE; CIRCULATING CHROMOGRANIN-A; ENDOCRINE NEOPLASIA TYPE-2; CRITICALLY-ILL PATIENTS; CLINICAL-PRACTICE; CALCITONIN LEVELS; SERUM CALCITONIN;

D O I：

10.1684/abc.2016.1188

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Neuroendocrine tumors (NET) are rare heterogenous tumors which prevalence is increasing. Their features vary by anatomical location, functionality and hormonal production. Their management needs a multidisciplinary approach. Functional tumors develop characteristic clinical syndromes in contrast to non-functional tumors that are diagnosed fortuitously or at advanced stage. NET can secrete many specific and general biomarkers. CgA is the most sensitive general marker. Its value should be interpreted along with the renal function and the gastrin level. Some new biomarkers such as NTproBNP, proGRP and NET gene transcripts have been identified. The latter are not yet routine in clinical practice. We present In this review biological biomarkers involved in NET with a focus on the assays and their use in clinical practice.

引用

页码：669 / 679

页数：11

共 108 条

[1] Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas [J].

Abou-Saif, A ;

Gibril, F ;

Ojeaburu, JV ;

Bashir, S ;

Entsuah, LK ;

Asgharian, B ;

Jensen, RT .

CANCER, 2003, 98 (02) :249-261

[2] Fast test: Clinical practice and interpretation [J].

Agin, Arnaud ;

Charrie, Anne ;

Chikh, Karim ;

Tabarin, Antoine ;

Vezzosi, Delphine .

ANNALES D ENDOCRINOLOGIE, 2013, 74 (03) :174-184

[3] Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study [J].

Ahmed, A. ;

Turner, G. ;

King, B. ;

Jones, L. ;

Culliford, D. ;

McCance, D. ;

Ardill, J. ;

Johnston, B. T. ;

Poston, G. ;

Rees, M. ;

Buxton-Thomas, M. ;

Caplin, M. ;

Ramage, J. K. .

[4] Monitoring the treatment of carcinoid disease using blood serotonin and plasma 5-hydroxyindoleacetic acid: three case examples [J].

Allen, K. R. ;

Degg, T. J. ;

Anthoney, D. A. ;

Fitzroy-Smith, D. .

ANNALS OF CLINICAL BIOCHEMISTRY, 2007, 44 :300-307

[5]

Amar L, 2007, TRAITE ENDOCRINOLOGI, P380

[6]

[Anonymous], 2003, THYROID, V13, P3

[7] Circulating markers for endocrine tumours of the gastroenteropancreatic tract [J].

Ardill, Joy E. S. .

ANNALS OF CLINICAL BIOCHEMISTRY, 2008, 45 :539-559

[8] Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors [J].

Arnold, Rudolf ;

Wilke, Alexandra ;

Rinke, Anja ;

Mayer, Christina ;

Kann, Peter Herbert ;

Klose, Klaus-Jochen ;

Scherag, Andre ;

Hahmann, Maik ;

Mueller, Hans-Helge ;

Barth, Peter .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (07) :820-827

[9] RELEASE OF PROTEIN FROM STIMULATED ADRENAL MEDULLA [J].

BANKS, P ;

HELLE, K .

BIOCHEMICAL JOURNAL, 1965, 97 (03) :C40-&

[10] Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma [J].

Barbet, J ;

Campion, L ;

Kraeber-Bodéré, F ;

Chatal, JF .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (11) :6077-6084

← 1 2 3 4 5 6 7 8 9 10 →